TITLE:  Direct Acting Antivirals for Chronic Hepatitis C genotype 1 in Select Populations: Emerging Evidence of Clinical Effectiveness and Safety

DATE:  28 April 2014

RESEARCH QUESTIONS

1. What is the evidence for clinical effectiveness and safety of treatment with boceprevir, telaprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who are co-infected with HIV?

2. What is the evidence for the clinical effectiveness and safety of treatment with boceprevir, telaprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have undergone liver transplant?

KEY MESSAGE

No relevant conference abstracts were identified regarding the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and PR combination treatments in patients with chronic hepatitis C genotype 1 who are co-infected with HIV or have undergone liver transplant.

METHODS

A limited literature search was conducted on key resources including PubMed, Embase, The Cochrane Library (2014, Issue 4), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2012 and April 15, 2014.

Selection was limited to conference abstracts to capture emerging evidence regarding the treatment of patients with chronic hepatitis C genotype 1 who are co-infected with HIV or have undergone liver transplant.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
RESULTS

No relevant conference abstracts were identified regarding the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir, or sofosbuvir and PR combination treatments in patients with chronic hepatitis C genotype 1 who are co-infected with HIV or have undergone liver transplant.

Additional conference abstracts of potential interest are provided in the appendix.

OVERALL SUMMARY OF FINDINGS

No relevant conference abstracts were identified regarding the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir, or sofosbuvir and PR combination treatments in patients with chronic hepatitis C genotype 1 who are co-infected with HIV or have undergone liver transplant, therefore no summary can be provided.
REFERENCES SUMMARIZED

Health Technology Assessments
No conference abstracts identified.

Systematic Reviews and Meta-analyses
No conference abstracts identified.

Randomized Controlled Trials
No conference abstracts identified.

Non-Randomized Studies
No conference abstracts identified.

PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Non-Randomized Studies

HIV Co-Infection


Liver Transplant


HIV Co-Infection and Liver transplant